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Summary
Background: Anthracyclines and taxanes are the most active
drugs against breast cancer and the search after their optimal
combination is under intensive investigation in both the ad-
vanced and early disease settings. A dose-finding study of
epidoxorubicin (E) and docetaxel (D) was conducted in ad-
vanced breast cancer (ABC) to define the maximum tolerated
dose (MTD) of the combination with and without granulocyte
colony-stimulating factor (G-CSF) support and to characterise
its toxicity and activity profile.
Patients and methods: Forty-two patients who received
neither palliative chemotherapy nor adjuvant anthracyclines
(55% with dominant visceral disease and 66% with ^2 sites
involved) with measurable/evaluable lesions, were treated at
four dose levels starting from E 75 mg/m2 and D 75 mg/m2 to
E 120 mg/m2 and D 85 mg/m2. A maximum of four cycles of
the combination was given every three weeks and four addi-
tional cycles of single agent D were allowed in responding
patients. Cardiac function was monitored at baseline and at
every second course by echocardiography.
Results: Febrile neutropenia (two patients) and prolonged,
severe neutropenia (absolute neutrophil count (ANC) <0.1 x
109/l for more than three days; one patient) defined the MTD
of the combination without G-CSF support at E 90 mg/m2
and D 75 mg/m2. G-CSF was then routinely administered
from the subsequent dose level of E 120 mg/m2 and D 75
mg/m2. The MTD with G-CSF support was established at E
120 mg/m2 and D 85 mg/m2 (one patient with neutropenic
fever together with failure of ANC recovery at day 21, three
patients with ANC less than 0.1 x 109/l for more than three
days, one patient with both and one patient with grade 4
thrombocytopenia and toxic death from typhlitis while neutro-
penic). No severe neurotoxicity, mucositis, or fluid retention
were observed and there were no clinical signs of cardiotox-
icity. Antitumour activity was not a primary endpoint of the
study: the overall response rate (ORR) in 40 evaluable patients
was 60% (95% confidence interval: 43%-75%, 58% in liver
disease, 84% in soft tissue) with no apparent dose-related effect.
After a median follow-up of 19 months (range 2-30+), the
overall time to progression (TTP) in nine patients without
maintenance hormonal therapy was five months.
Conclusions: The combination of E and D proved to be an
effective and safe regimen in poor- prognosis patients with
ABC. G-CSF support allowed higher doses to be delivered
safely but dose escalation did not translate into improved
response rates (RR). The MTD without growth factors support
was used, in a phase II trial, which also included patients with
previous anthracycline-containing adjuvant regimens.
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Introduction
Anthracyclines are among the most active of the first-
line drugs in advanced breast cancer (ABC), achieving
objective response rates (ORR) of 40%-50% when used
as single agents [1] and of up to 70% in combination
regimens [2]. In anthracycline-based combinations, doxo-
rubicin (DOX), the most commonly used of these com-
pounds, can be replaced by epirubicin (E) without loss
of efficacy [3,4] and with decreased cardiotoxicity [5].
Nonetheless, the anthracycline-based regimens have
not dramatically changed the overall survival of these
patients, because of the low complete remission (CR)
rate (5%-15%) and the short duration of responses.
Single agent docetaxel (D) has demonstrated high
activity as first-line therapy in ABC: with ORRs of 54%
to 68% this drug appears to be at least as effective as
standard combination therapies [6-9]. Moreover, the
ORR of 41% reported in patients with anthracycline-
resistant disease [10] is the highest yet seen with a single
agent. A recent randomised phase III trial showed also
an improved overall survival (11.4 vs. 8.7 months, P =
0.0097) as compared to the combination of mitomycin C
and vinblastine in patients with metastatic disease who
have previously failed an anthracycline-containing regi-
men [11]. Although both D and the anthracyclines are
substrates for MDR-related efflux mechanisms, the differ-
ences in their mechanisms of action (microtubular as-
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sembly disturbance vs. topoisomerase II inhibition)
might explain these results. The 100 mg/m2 recom-
mended dose of D might be more active than 75 mg/
m2; the apparent dose-response relationship is being
investigated prospectively in an ongoing multicenter,
randomised trial of D 100 mg/m2 vs. 75 mg/m2 as first-
or second-line therapy in ABC [7].
Several trials on the combination of paclitaxel (P)
(given by ^ 24-hour infusion) with DOX (given by bolus
or by prolonged infusion) in ABC suggested a sequence-
dependent tolerability, with higher MTDs when DOX
was administered before P than with the opposite
schedule [12-14]. PK analysis showed that, when P was
given before DOX, the elimination phase of DOX was
prolonged and the maximum concentration and the area
under the concentration-time curve (AUC) were in-
creased [15]. This observation was not confirmed by
Gianni et coworkers who found a PK interference
between P (given over three hours) and DOX, with
increased plasma concentrations of DOX and its metab-
olite doxorubicinol, with both sequences of administra-
tion [16]. On the contrary, P seems to be associated with
an increased urinary excretion of E, the pharmaco-
dynamic relevance of which is currently under investiga-
tion [17]. The available clinical data indicate so far that
the sequence DOX and P is the one associated with the
best tolerability.
As a result of the high antitumour activity and toxicity
profile reported with P and DOX [12-14, 18-21] with
20% congestive heart failure (CHF) after cumulative
doses of DOX > 360 mg/m2 [19], a phase I-II trial in
42 patients with D and DOX as first-line chemotherapy
in ABC was designed and conducted by Dieras et al.
[22]. The MTD was reached at DOX 50 mg/m2 and D
85 mg/m2 with sepsis as the dose-limiting toxicity
(DLT). Antitumour activity was seen at all dose levels
with an ORR of 81% and an objective RR of 83% in
patients with liver involvement. The recommended
doses, without G-CSF support, were DOX 50 mg/m2
and D 75 mg/m2, or 60 mg/m2 of both drugs. No cases
of CHF or significant decrease in left-ventricular ejection
fraction (LVEF) were observed at a median cumulative
dose of DOX of 392 mg/m2.
As a consequence of an almost two-fold faster elimi-
nation and, thus, a 40% smaller area under the curve
than equimolar doses of DOX, E might be given at
higher doses. In fact, the MTD was established at
180-150 mg/m2 in untreated and previously treated
patients respectively [23, 24] and in several phase II
trials E could be safely administered as single agent at
doses ranging from 120 mg/m2 to 150 mg/m2 every three
weeks [25].
Three randomised trials in ABC showed that higher
doses of E, either alone or in combination, induced a
significantly greater RR, suggesting a clinically relevant
dose threshold for E (>90 mg/m2) [26-28].
The combining of P with E has been motivated pri-
marily by the potential for decreasing the cardiac toxicity
observed after high cumulative doses of DOX in combi-
nation with P [19]. These trials have thus far shown good
cardiac tolerability and significant antitumour activity,
the latter being somewhat lower than that reported with
the equitoxic combination with DOX [29-31].
The International Breast Cancer Study Group
(IBCSG) conducted a dose-finding phase I trial of E
and D as first-line therapy in ABC. The primary aim of
the study was determine the MTDs of the combination
given every three weeks with and without G-CSF support.
Secondary aims were the evaluation of the toxicity profile
and of the antitumour activity of the combination.
Patients and methods
Patients with histologically or cytologically documented raetastatic or
locally advanced breast cancer who had received no prior chemotherapy
for metastatic disease were eligible. Neoadjuvant chemotherapy com-
pleted at least six months prior to study entry and not containing
anthracyclines was allowed. Prior hormonal therapy for advanced
disease was allowed. Criteria for inclusion were as follows: adequate
hematologic (ANC >2.0 x 1O9/1, platelet count > 100 x 109/l) renal,
hepatic (liver function tests currently recommended for treatment with
docetaxel) [32] (and cardiac function (LVEF > 50% by echocardiog-
raphy), measurable or evaluable disease, written informed consent.
Baseline evaluation was performed within four weeks before study
entry and included history, physical examination, chest X-ray, com-
plete blood cell count (CBC), biochemistry, electrocardiogram (ECG)
and radiological imaging of indicator lesions (CT scan, bone scan
and/or bone selected segments). During therapy, CBC was performed
at least twice weekly and biochemistry before each cycle. Tumour
response of measurable and evaluable sites of disease and cardiac
function monitoring (ECG and echocardiography) were repeated after
every second course. Treatment was discontinued in case of CHF of
any grade and/or of a significant reduction in LVEF ( ^ 10% associated
with a decline to a level ^ 50%) confirmed one week later.
Patients were allowed a maximum of four cycles of the combina-
tion: four additional cycles of single-agent D at the same dose level
were available to those who responded. Response was defined accord-
ing to WHO criteria [33]. The imaging of all cases was reviewed by an
independent radiologist. The duration of response was calculated from
first demonstration of response to documented disease progression.
TTP was dated from initial treatment to progression, last contact or
start of further antitumour therapy. Osteolytic lesions were considered
evaluable, but not measurable, while sclerotic metastases were deemed
not evaluable.
D (Taxotere) (RP 56976) was supplied by Rhone-Poulenc Rorer as
a concentrated sterile solution containing 40 mg/ml = 80 mg/2 ml/vial
in polysorbate 80 (Tween JE 80). The appropriate solvent for the premix
solution of D was also supplied as a sterile solution in vials of 6 ml
containing ethyl alcohol 95%: water 13:87 (W: W).
E (farmorubicin RTU) is supplied in vials containing 10 mg, 20 mg,
and 50 mg of epidoxorubicin hydrochloride as a ready to use solution.
E was administered intravenously as a 15-minute infusion followed
after one-hour interval by D given as a one-hour infusion on day 1. A
three-day prophylactic medication with oral dexamethasone (8 mg) 13
hours, 7 hours and 1 hour before D and then twice daily on days 1 and 2
was routinely administered in combination with oral cimetidine (300
mg) once daily. Prophylactic antiemetic treatment was given according
to investigators' routine practice. Prophylactic oral antibiotics were
recommended in case of ANC below 0.5 x 109/l. Therapy was admin-
istered in the outpatient clinic every three weeks, provided the ANC
was ^2.0 x 109/l and the platelet count was > 100 x 109/l the day
scheduled for retreatment. If recovery had not occurred after a max-
imum delay of three weeks patients were withdrawn from the study.
The starting dose of E and D was 75 mg/m2 and was selected on the
basis of the data on tolerability of the combination of DOX and D [22].
541
At least three patients had to be treated at each dose level and if a
DLT occurred in one of them during the first cycle, a total of six
patients had to be entered at the same dose. Toxicity was recorded
according to the NCI Common Toxicity Criteria (CTC). Each cycle
was considered fully evaluable for haematological toxicity only in case
of at least a twice weekly CBC assessment. DLTs were ANC less than
0.5 x 1O9/1 for more than seven days, ANC less than 0.1 x 109/l for
more than three days, febrile neutropenia (ANC <0.5 x 109/l and
single elevation in oral temperature to > 38.58 °C during a 24-hour
period) [34], grade 5= 3 mucositis and failure of ANC recovery at day
of retreatment.
G-CSF support (150 ug/m2/day subcutaneously from day 2 to day
19) was initiated in the individual patient at the subsequent cycle in
case of DLT and at the next higher dose level if two or more of three
patients or three or more of six patients presented a DLT for which the
administration of G-CSF was indicated. This dose was defined to be
the MTD without G-CSF support.
The MTD with G-CSF support was defined as the one at which,
during the first cycle, more than two of three or three of six patients
suffered a DLT in spite of receiving G-CSF support or a DLT for which
G-CSF was not indicated, ie grade 4 thrombocytopenia, grade ^ 3
nonhematologic toxicity (except for alopecia and nausea and vomiting)
or persistence of grade >2 nonhematologic toxicity at scheduled
retreatment. The recommended phase II dose was defined as the
MTD without G-CSF support and its evaluation was expanded in 20
additional patients.
Results
From July 1996 to September 1997, a total of 42 patients
with metastatic or locally ABC entered the trial (Table 1),
28 patients in the dose-escalating part of the study and
14 in the phase II part at the recommended dose. Twenty-
three patients (55%) had dominant visceral disease and 28
(66%) had at least two metastatic sites. A total of 235
courses of therapy were administered at four different
dose levels:
Table I. Patients characteristics.
Dose level Epirubicin (mg/m2) Docetaxel (mg/m2)
1
2
3a
4a
75
90
120
120
75
75
75
85a
' G-CSF support from cycle 1
Sixty-seven percent of the cycles (159) were fully evalu-
able for hematologic toxicity as no dose reductions were
applied and no G-CSF support was added (Table 2).
Treatment delay occurred in 17 patients due to logistic
problems only, whereas a reduction to the lower dose
level was applied to eight patients, as a consequence
either of febrile neutropenia (six patients), or of grade 3
stomatitis and diarrhoea (one patient each). All patients
were evaluable for non-haematological toxicity (Table 3).
One patient died due to typhlitis and small bowel perfo-
ration while neutropenic after the first cycle at the high-
est dose level. Twelve responding patients received the
allowed four additional cycles of single-agent T at the
same dose delivered when in combination.
Entered
Age
Median
Range
ECOG performance status 0-1
Oestrogen receptors
Positive
Negative
Unknown
Prior chemotherapy
Prior hormonal treatment
Metastatic
Dominant disease site
Viscera (liver)
Soft tissue
Loco-regional
Bone
Number of metastatic sites
1
>2
Number of patients
42
51.5
32-68
42
18
14
10
13
16
5
23(12)
4
8
7
14
28
Hematologic toxicity
Grade 4 neutropenia was universal and represented the
main hematologic toxicity (Table 2): overall, the use of
G-CSF allowed higher doses to be delivered with similar
depth and duration of ANC nadirs which lasted a
median of four days at all dose levels with a maximum
of 10 days. Among six patients treated at the lowest dose
level (E 75 mg/m2 and D 75 mg/m2) without G-CSF
support, only one patient experienced a DLT after the first
cycle (ANC less than 0.5 x 109/ and less than 0.1 x 109/l
for more than seven days). At the subsequent level of
dose (E 90 mg/m2 and D 75 mg/m2), three out of six
patients required G-CSF support after the first cycle
(neutropenic fever in two patients and ANC less than
0.1 x 109/l for more than three days in one patient) thus
defining the MTD without G-CSF support. Thereafter,
G-CSF was added from the first cycle in all patients
entering the highest dose level. At E 120 mg/m2 and D
75 mg/m2 (third dose level) two out of seven patients
suffered a DLT (one neutropenic fever and one ANC less
than 0.1 x 1O9/1 for more than three days): in the first
patient the dose of E was reduced to 90 mg/m2 according
to protocol while in the second patient the investigator
decided to continue at the same doses with no major
hematologic toxicity observed at the subsequent cycles.
At the fourth level of dose (E 120 mg/m2 and D 85
mg/m2) six out of nine patients experienced a DLT thus
defining the MTD (one with neutropenic fever together
with failure of ANC recovery at day 21, three with ANC
less than 0.1 x 109/l for more than three days, one with
both). Dose reductions according to protocol were im-
plemented in the two patients with febrile neutropenia
while the remaining three patients continued to receive
the same amount of E with signs of cumulative myelo-
suppression in only one of them. The sixth patient with
DLT died from typhlitis while neutropenic after the first
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Table 3. Grade > 2 non-hematologic toxicities.Table 2. Overall incidence of neutropenia and neutropenic fever.
Dose level No. Total Median ANC Febrile neutro- G3^» DLT Dose level Nausea /vomiting Neurotox Mucositis Asthenia
(mg/m2) of cy/ nadir (range) penia ANC (mg/m2) (%cy) (%cy) (%cy) (%cy)
pts evaf .
Number Number % cy
of ofcy
patients (%)
D75
E75
D75
E90
D75
E120d
D85
E 120d
6 29/24 0.21 (0.03-2.34) 1 1 (3) 92 lb
20 116/62 0.26(0-1.5) 9 10(16) 87 3C
7 41/34 0.30(0-2.28) 2 2(5) 83 2'
9 49/39 0.31(0-3.15) 5 8(20) 88 6r
a
 Excluded cycles with G-CSF support and modified dose.
b
 ANC <0.5 x 109/l and <0.1 x 109/l > 7 days.
c
 Febrile neutropenia (two patients), ANC < 0 1 x 109/l > 3 days (one patient).
d
 G-CSF support from cycle 1.
e
 Febrile neutropenia (one patient), ANC <0.1 x 109/l > 3 days (one patient).
f
 Febrile neutropenia and failure of ANC recovery at day 21 (one patient), ANC
<0.1 x l09/l > 3 days (three patients), both (one patient), typhlitis (one patient)
cycle for a locally advanced disease: the patient pre-
sented one week after treatment with abdominal pain
and grade 4 neutropenia and thrombocytopenia. She
was admitted to the hospital and suddenly developed a
septic shock with large bowel perforation and blood
cultures positive for Clostridium septicum. The patient
underwent three subsequent bowel resections with a
picture of a diffuse, acute ischemic colitis requiring first
a total colectomy followed by repeated jejunal perfora-
tions. Tumour infiltration, vasculitis, septic emboli or
atheromatosis could not be found in the pathologic
specimens. Post mortem examination was not performed.
Overall, febrile neutropenia occurred in 13% of cycles
(Table 2) but was associated with complications in only
one patient at the highest dose level. Its incidence in-
creased with the increase of E doses (3% and 16% of
cycles at first and second dose level, respectively, without
G-CSF support). G-CSF seemed to allow higher doses to
be delivered with unaltered occurrence of febrile neutro-
penia when E doses were concerned (5% of cycles at the
third dose level) but not when D doses were increased
too (20% of cycles at the fourth dose level with one toxic
death). In the group of 14 patients treated in the second
part of the study at the dose denned as MTD without
G-CSF support (E 90 mg/m2 and D 75 mg/m2) the
overall incidence of febrile neutropenia was 9%.
Grade 3-4 anemia and thrombocytopenia occurred
only in 4% of cycles at the highest dose level and were of
no clinical significance.
Non-hematologic toxicity
Non-hematologic toxicity was generally mild to moderate,
aside from universal alopecia (Table 3). Asthenia was
common, occasionally severe, especially in the early
days following corticosteroid interruption. Mucositis,
neurotoxicity, fluid retention, arthralgia, myalgia and
D75
E75
D75
E90
D75
E120a
D85
E 120"
7
7
2
14
3
7
0
10
1
 G-CSF support from cycle 1.
Table 4. Impairment of cardiac function.
> 10% LVEF decrease
Patient
A
B
C
D
E
F
G
D/E dose
level
2
2
2
2
2
2
3
Cycle
number
2
4
2
6
2
4
4
LVEF decrease
in units
13
14
10
11
14
16
11
Cumulative E
(mg/m2)
180
360
180
540a
180
360
480
a
 Patient received six cycles of the combination by investigator's
decision.
fluid retention were present in some patients, with no
significant difference in incidence and severity at the
highest dose levels, and were generally not severe. Grade
4 diarrhoea in association with grade 2 stomatitis and
febrile neutropenia was experienced by one patient only
treated at E 90 mg/m2 and D 75 mg/m2.
In patients receiving four additional cycles of D,
no signs of cumulative neurotoxicity, fluid retention,
arthralgia, myalgia or skin toxicity were reported.
Cardiac toxicity
No clinically evident cardiac toxicity has been seen so far.
Overall, the cumulative E dose ranged from 120 mg/m2
to 540 mg/m2 with a median of 480 mg/m2. Six patients
treated at E 90 mg/m2 and D 75 mg/m2 and one at E 120
mg/m2 and D 75 mg/m2 developed a > 10% transient
and asymptomatic decrease in LVEF after cumulative
doses of E ranging from 180 mg/m2 to 540 mg/m2
(Table 4) with no absolute fall below 50%. In none of
these patients a known predisposing factor to anthra-
cycline cardiotoxicity was evident.
Antitumour activity
Two patients were not evaluable for response because of
toxic death after the first cycle in one case and lack of
measurable /evaluable disease in the other. Among 40
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Table 5. Antitumour activity.
Dose level Number of CR(%) PR(%) SD (%) PD(%)
(mg/m2) patients
(evaluable)
D75/E75
D75/E90
D75/E 120
D85/E120
6(6)
20(19)a
7(7)
9(8)b
0
0
0
1 (2.5)
3(50)
11(58)
4(57)
5(64)
1(17)
7(37)
1(14)
1(12)
2(33)
1(5)
2(29)
1(12)
a
 One patient not evaluable due to lack of measurable/evaluable
disease.
b
 One patient not evaluable due to toxic death after the first cycle.
Table 6. Tumour response by disease site.
Site
Liver
Lung
Locoregional
Soft tissue
Bone
Total
12
11
15
19
21
Evalu-
able
12
11
12
19
16
CR (%)
0
0
0
11
0
PR (%)
58
64
50
74
6
NC (%)
33
27
50
16
75
RR (%)
58
64
50
84
6
patients evaluable for response, 38 patients had at least
one measurable tumour parameter. The ORR was 60%
(95% CI: 43%-75%) with CR in one patient (2.5%),
tumour progression (PD) in 15% of patients and no
differences in response rate among the different dose
levels (Table 5). Median time to best response at the
different dose levels ranged from 1.2 to 2.9 months.
Overall, the addition of four cycles of single-agent D
did not improve the antitumour activity achieved with
the initial four cycles of the combination: only one pa-
tient with stable disease in liver and bone achieved a PR
at the end of a total of eight cycles. Adjuvant chemo-
therapy did not seem to affect antitumour response;
among 13 patients who completed adjuvant treatment at
least six months prior the inclusion in the present trial
(median 28 months, range 4-180) seven achieved a PR
and one a CR with an ORR of 61.5%. All disease sites
responded to the combination, irrespective of the dose
administered (Table 6). The RR of the combination
given as neoadjuvant treatment in locally advanced dis-
ease (12 evaluable patients) was 50%. The presence of
bone metastases did not significantly affect disease
response evaluation: in two patients with impressive
shrinkage of locoregional disease the difficulty of bone
disease assessment impaired the overall response deter-
mination.
At a median follow-up time of 19 months (range
2-30+) 14 out of 23 patients with a PR were censored
without evidence of disease due to maintenance hormo-
nal therapy (10 patients), surgical treatment (3 patients)
or chemotherapy (1 patient); in the remaining 9 patients
the median duration of response was seven months
(range 3-19+) and the overall TTP was five months. The
only CR observed was achieved in one patient with
lung and mediastinal metastases and carcinomatous
lymphangitis who subsequently developed bone metas-
tases. Median survival has not been reached: 14 patients
have died (33%) and 28 (67%) survive.
Discussion
Several trials exploring the combination of anthracy-
clines and taxanes in breast cancer have been recently
conducted or are under way both in the advanced and in
the adjuvant disease setting.
Four phase I studies evaluated the combination of E
and D as first-line treatment in ABC [35-38], with a
total of 196 patients enrolled (Table 7). The toxicity
profile was comparable between trials, with grade 4
neutropenia almost universal, rarely complicated, and
lack of clinically significant cardiac toxicity.
As regards antitumour response the ORR ranged
from 52% in the Greek trial [38] to 69% and 76% (8%
and 14% CRs) in the French [35] and the Italian trial [36]
respectively, with sustained activity at all disease sites.
The recommended dose without G-CSF support is not
yet established in the Greek study and varied from E 100
mg/m2/D 75 mg/m2 [35] to E 60 mg/m2/D 75 mg/m2
[37] in the trials with mature results.
Table 7. Phase I studies of docetaxel/epirubicin in ABC.
Study
Pagani
Kerbrat [35]
Venturini [36]
Trudeau [37]
Panagos [38]
Number of
patients
42
65
25
19
45
Design
E+D (one hour later)
Concomitant E+D
Concomitant E+D
E+D (one hour later)
1 x concomitant E+D
2 x E+D (one day later)
G-CSF
From third level
No
No
No
AtMTD
DLT
Febrile neutropenia
Prolonged neutropenia
G4 neutropenia
Febrile neutropenia
Prolonged neutropenia
Febrile neutropenia
Prolonged neutropenia
GI toxicity
Febrile neutropenia
G4 neutropenia
MTD (mg/m2)
D75/E90 (no G-CSF)
D85/E120 (+ G-CSF)
D75/E110
D60/E90
D80/E75
D75/E75
1 x D8O/E7O
2 x D90/E80 (ongoing)
ORR (%)
60
69
76
NA
52 (27 patients)
544
The results of the present phase I trial show that
haematological toxicity represents the DLT of the com-
bination and confirm that E and D can be given safely
without G-CSF support at doses of 90 mg/m2 and
75 mg/m2, respectively. No indications of cumulative
toxicity emerged in the 159 evaluable cycles. The addi-
tion of G-CSF allowed higher doses of both drugs to be
delivered without a significant worsening in hematolog-
ical toxicity, in particular as regards depth and duration
of ANC nadir. The incidence of febrile neutropenia was
quite high (13%) but it was short lasting and uncompli-
cated in the majority of patients: 60% of the febrile
episodes did not require hospitalisation and could be
resolved with oral antibiotics. Routine administration of
oral prophylactic antibiotics during grade 4 neutropenia
and the careful clinical and laboratory evaluation in
experienced cancer centres may partly explain this fa-
vourable clinical outcome.
At the cumulative dose of anthracycline delivered in
this study, E/D did not cause any clinically significant
cardiac toxicity, as compared to the 20% of CHF
previously reported for a median cumulative dose of
DOX of 480 mg/m2 [19]. These data confirm the lack of
enhanced cardiotoxicity reported with DOX/D, despite
median cumulative doses of DOX exceeding 360 mg/m2
[22] and the good cardiac tolerability of E/P [29-31]. It
should be noticed, however, that in the present trial
patients could receive a maximum of four cycles of the
combination, up to a maximum cumulative dose of E of
480 mg/m2 at the highest dose levels, significantly lower
than the dose of 360 mg/m2 recommended for DOX in
combination with P; taking a conversion factor for
cardiotoxicity of 1.8, this should correspond to a dose of
E of 650 mg/m2.
Preclinical studies have shown that the concentra-
tions of E in serum and tissues (heart, kidney and liver)
are significantly higher in mice receiving P as compared
to E alone [39]. More recent studies in mice treated with
P, D and DOX suggest that both taxanes might increase
the concentration of DOX in many tissues, including
hearth [40].
The lack of both cumulative hematological toxicity
and clinical cardiotoxicity after four cycles of the combi-
nation justifies the evaluation of more prolonged treat-
ments with the administration of higher cumulative
doses of E/D.
In the present study the ORR in 40 evaluable patients
was 60%: this result is comparable to those achieved
both in the French Anti-Cancer Centres [35] and in the
Italian single centre study [36] but seem somewhat lower
than those reported by some authors when DOX is
combined either with P [19, 21] or D [22], mainly as
regards the CR rate.
Different patient characteristics and the small sample
size of most of these studies may partly explain these
different results: the difficulty to assess tumour response
in bone, where both osteolytic and sclerotic lesions often
coexist, could possibly affect the ORR in our series,
where bone disease was present in 47% of patients.
Tumour response was similar at all dose levels: dose
escalation of E was apparently associated with a slightly
higher RR (67% ORR with E at 120 mg/m2 vs. 56%
ORR with E at 75 mg/m2 to 90 mg/m2) but the different
dose levels were not designed to address this specific
question and the number of patients is too small to draw
any significant conclusion. This observation seem to
confirm the data recently published on the comparable
ORR and OS for doses of E ^90 mg/m2 [41] and
prompted us to evaluate the combination of E 90 mg/m2
and D 75 mg/m2 without G-CSF in an extended phase
II study recently completed.
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